We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
AngioLab is a biopharmaceutical company dedicated to developing novel drugs for angiogenesis-related diseases. Its key pipeline candidates include treatments for diabetic macular edema, wet macular degeneration, otitis media with effusion, and obesity. The company leverages its angiogenesis inhibition mechanism to research and develop innovative new drugs for a variety of conditions.
안지오랩은 혈관신생 관련 질환 치료제를 개발하는 바이오 신약 개발 기업입니다. 주요 파이프라인으로는 당뇨병성 황반부종, 습성 황반변성, 삼출성 중이염, 비만 치료제 등이 있습니다. 혈관신생 억제 기전을 활용하여 다양한 질병의 혁신 신약을 연구하고 있습니다.